Earning Preview: Staar Surgical revenue is expected to decrease by 13.28% this quarter, and institutional views are bullish

Earnings Agent10-29

Abstract

Staar Surgical will release fiscal third-quarter 2026 results on November 4, 2026 Post-Mkt; our preview consolidates the latest quarterly actuals, consensus projections for revenue, EBIT, and EPS with year-over-year comparisons, and synthesizes recent institutional views and corporate updates to frame the near-term setup.

Market Forecast

Consensus for the fiscal third quarter points to revenue of 78.76 million US dollars, EPS of 0.05 US dollars, and EBIT of 2.48 million US dollars; these imply year-over-year changes of -13.28%, -67.79%, and -63.41%, respectively. Management has not issued explicit gross margin or net margin guidance for the quarter. The core business continues to be anchored by direct, non-consignment product sales and supported by consignment arrangements; order flow is expected to normalize against last year’s unusual quarterly mix. The most promising revenue engine remains non-consignment sales, which contributed 80.92 million US dollars last quarter; set against the company’s overall 111.05% year-over-year revenue increase in that period, investors will watch whether this channel sustains volume momentum as mix normalizes.

Last Quarter Review

In the fiscal second quarter ended July 3, 2026, Staar Surgical reported revenue of 93.54 million US dollars (+111.05% year over year), gross margin of 74.55%, GAAP net profit attributable to shareholders of 8.06 million US dollars with a net margin of 8.61%, and adjusted EPS of 0.16 US dollars (+147.06% year over year). A notable highlight was broad-based upside versus prior expectations: revenue exceeded the quarter’s estimate by 2.95 million US dollars, EBIT of 10.10 million US dollars topped estimates by 1.70 million US dollars, and EPS of 0.16 US dollars modestly surpassed the 0.15 US dollars consensus. From a business-mix perspective, non-consignment sales delivered 80.92 million US dollars (86.52% of quarterly revenue) while consignment contributed 12.61 million US dollars (13.48%), with overall revenue expanding 111.05% year over year.

Current Quarter Outlook

Core operating performance and revenue cadence

The central variable for the fiscal third quarter is the comparison base, which is complicated by an extraordinary, previously disclosed one-time order recognized in fiscal third quarter 2025 of 25.90 million US dollars. That prior anomaly elevates the bar for year-over-year growth in the current quarter and is consistent with consensus now pointing to 78.76 million US dollars of revenue, implying a 13.28% decline year over year despite the company’s strong second-quarter rebound. This dynamic sets a framework in which sequential trends and underlying order quality matter more than headline year-over-year growth rates. Order normalization and surgical volumes are the second key determinant. After an unusually high revenue print in the prior-year quarter, management’s ability to show steady procedure throughput, stable backlog conversion, and predictable replenishment across accounts will be closely watched. Softness, if any, may stem from timing effects rather than demand erosion; investors will parse management’s commentary for confirmation that case volumes and reorder frequencies remain intact or on a measured upward trajectory. Gross margin resilience following the 74.55% result in the last quarter is a third focal point. Mix between premium products and routine lenses, channel configuration between non-consignment and consignment, and throughput efficiencies can all influence margin capture in the quarter. While there is no explicit gross margin guide, the previous quarter’s outcome provides a high baseline; any update on input costs, manufacturing yields, or promotional dynamics may frame the nearer-term margin corridor even without a formal percentage target. On operating profitability, consensus EBIT of 2.48 million US dollars and EPS of 0.05 US dollars reflect expectations for lower operating leverage than in the second quarter; this again ties back to the unusually tough comp and typical third-quarter activity patterns. Evidence of disciplined expense control—particularly around commercial investments and R&D—can support a path to narrowing the gap between revenue and EBIT outcomes versus the prior quarter, even if absolute growth remains below the second-quarter level. Finally, management color on the fourth quarter demand setup will likely overshadow any one-off quarterly items. If the company signals visibility into steady schedules, normalized distributor inventories, and a path back to double-digit growth in core markets absent last year’s anomalies, investors may treat a third-quarter miss-or-beat as transitory relative to the trajectory into fiscal year-end.

Largest growth opportunity and mix implications

The company’s most scalable revenue lever remains its non-consignment sales engine, which generated 80.92 million US dollars last quarter and represented 86.52% of revenue. The ability to sustain growth here rests on case adoption, account penetration, and repeat purchase rates that translate into consistent reorder behavior. While the prior quarter benefited from a favorable mix, confirmation that the non-consignment channel can expand independent of last year’s one-time recognition is essential for recalibrating medium-term growth expectations. Geographic execution is an adjacent driver of growth within the business. Management disclosed that, excluding the Middle East, EMEA grew 12% year over year in the prior quarter; a similar pattern of demand health, if reiterated, would suggest solid underlying momentum even as certain subregions face macro or geopolitical headwinds. Conversion of training and education investments into incremental procedures, particularly in markets with established refractive practices, can compound volume growth in a way that elevates the non-consignment contribution without requiring outsized price actions. Product innovation and commercialization processes are also aligned with this growth opportunity. Recent leadership appointments—David Bailey as chief commercial officer and Ben Park as chief technology officer in September 2026—may catalyze tighter linkage between product roadmap and go-to-market execution. In the near term, investors will look for indicators such as account pipeline growth, surgeon onboarding metrics, and early feedback on any product enhancements that could support premium mix and, by extension, sustain the high-70s gross margin profile observed last quarter. Clear commentary on training utilization rates and conversion to paid procedures would further substantiate the revenue quality narrative.

Key stock-price drivers this quarter

Revenue versus consensus is the first-order catalyst. With the market centered on 78.76 million US dollars, outperformance would argue that normalization after last year’s one-time order is progressing faster than expected, whereas underperformance would raise questions about procedure pacing or distributor inventory dynamics. Equally important is the composition of revenue—investors will scrutinize the balance between non-consignment and consignment channels for implications to both gross margin and revenue durability into the fourth quarter. The second driver is profitability sensitivity to operating expense timing. Consensus EBIT of 2.48 million US dollars and EPS of 0.05 US dollars leave little room for cost slippage; even modest increases in selling or clinical support costs could compress operating margins. Conversely, evidence of cost discipline that protects commercialization capacity while moderating near-term spending would be taken as a positive leading indicator for operating leverage once year-over-year compares normalize. Capital allocation is the third driver. The board’s authorization on September 25, 2026 of a share repurchase program of up to 50.00 million US dollars, supported by 181.50 million US dollars in cash, cash equivalents, and available-for-sale investments and no debt as of July 3, 2026, provides a backstop for EPS and signals confidence in cash generation. Investors will watch for any early activity under the authorization and for management commentary on capital return pacing relative to investment priorities in commercial and R&D initiatives. A fourth factor is regional demand commentary, particularly in EMEA. The company noted that excluding the Middle East, EMEA grew 12% year over year in the second quarter; whether this cadence persisted through the third quarter could influence how investors interpret the headline revenue print. Consistent demand signals, combined with clean inventory positions and stable pricing, would support a constructive interpretation even if comparisons remain distorted by last year’s one-time order. Finally, any qualitative forward guideposts for the fourth quarter and early fiscal 2027—such as expected case volumes, channel inventory assumptions, or commercial rollout milestones—could overshadow the quarter’s reported figures. Clarity on these items may drive more durable stock reactions than the absolute third-quarter EPS number, given the known compare headwinds and the company’s healthy balance sheet and margin structure.

Analyst Opinions

Bullish views dominate recent institutional commentary, accounting for approximately 67% of the opinions we reviewed versus 33% bearish. Stifel upgraded Staar Surgical to Buy with a 31.00 US dollars price target in late September 2026, highlighting an improving execution setup and a favorable skew to risk-reward as operational momentum rebuilds. Wedbush reiterated an Outperform rating in mid-August 2026 and adjusted its price target to 37.00 US dollars, citing the company’s return to profitability in the second quarter and visibility into sustained gross margin strength as volumes recover. Multiple updates across August to September reiterated that the average rating sits near Hold while individual positive revisions are emerging, suggesting that the market is reassessing the earnings power as transitory headwinds fade. We interpret the bullish majority as grounded in three pillars. First, the second-quarter rebound—93.54 million US dollars in revenue, 74.55% gross margin, 8.06 million US dollars in GAAP net income, and 0.16 US dollars adjusted EPS—demonstrated that revenue scale can quickly restore operating leverage when procedure volumes are in-line. Second, high cash reserves of 181.50 million US dollars with no debt and a newly authorized 50.00 million US dollars repurchase create flexibility to support EPS while funding growth initiatives. Third, leadership moves in September 2026—adding a seasoned commercial chief and a technology head with prior experience at a leading dental aligner company—signal attention to both near-term go-to-market execution and longer-term innovation. From a near-term perspective, bullish analysts generally frame the third quarter as a transitional print shaped by last year’s one-time order, with more emphasis on sequential trajectory, channel mix, and early fourth-quarter indicators than on the headline year-over-year percentage. This view is consistent with consensus modeling: revenue at 78.76 million US dollars, EBIT at 2.48 million US dollars, and EPS at 0.05 US dollars, all of which embed conservative assumptions on operating leverage and reflect the base-effect distortion. The focus is on whether management commentary confirms stable underlying demand—e.g., steady case volumes and reorder patterns—and whether gross margin remains resilient despite the smaller revenue base versus the prior quarter. Looking beyond the quarter, bullish commentators expect that the company’s dominant non-consignment sales channel can sustain volume improvements without reliance on one-time orders, aided by surgeon training and commercial support. They also point to signs of healthy underlying demand in EMEA excluding the Middle East, which grew 12% year over year in the second quarter, as a directional indicator of the business’s capacity to expand even where macro visibility is mixed. If management can maintain expense discipline, demonstrate progress on commercialization initiatives, and begin to deploy the buyback authorization thoughtfully, these analysts believe the setup into the fourth quarter and early fiscal 2027 becomes more favorable. In sum, the prevailing institutional stance is cautiously optimistic: despite a third quarter that likely reflects complex compares, the balance of evidence—margin structure, cash strength, incremental leadership depth, and channel-driven revenue quality—supports a constructive outlook. The debate now centers on the slope of improvement rather than its direction, and the upcoming call will be judged on signals that validate durable demand and measured operating leverage as the business cycles past last year’s anomalies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment